DOCSLIB.ORG

Piribedil: Sleep Attacks, Also in Patients Without Parkinson's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piribedil: Sleep Attacks, Also in Patients Without Parkinson's Disease Translated from Rev Prescrire May 2013; 33 (355): 351 Piribedil: sleep attacks, also in patients without Parkinson’s disease Piribedil is a dopamine agonist used According to the definition adopted in drug having a direct role in sleep attacks, in Parkinson’s disease and a variety of this study, sleep attacks are “events of and probably a similar role to that of other clinical situations although its overwhelming sleepiness that occur with- other dopamine agonists. efficacy has not been demonstrated. out warning or with a prodrome suffi- ciently short or overpowering to prevent In practice: piribedil has little value. A study based on the French nation- protective measures” (7). Piribedil has not been shown to be an al pharmacovigilance database iden- The French pharmacovigilance data- effective treatment for vascular disorders. tified and analysed 7 reports of sleep base contained 7 reports of sleep attacks It is not the first-choice dopamine agonist attacks attributed to piribedil in that met this definition in patients without in Parkinson’s disease, and its value is patients without Parkinson’s disease. Parkinson’s disease who were taking unclear (1,3,8). Unnecessary exposure of The case reports are detailed and indi- piribedil. The average age of these patients to the adverse effects of piribedil cate that piribedil has a direct role in 7 patients was 69 years. The daily dose is not justified. It is better to use drugs with the onset of sleep attacks. ranged from 20 mg to 150 mg (median: demonstrated efficacy instead. 50 mg). Six patients were using piribedil ©Prescrire To spare patients unnecessary for a variety of vascular disorders, and the exposure to the adverse effects of other patient was taking it for essential a- The main adverse effects of dopamine agonists are: gas- piribedil, it is better to avoid using tremor. In 6 cases, piribedil was the only trointestinal disorders; hypotension, particularly orthosta- piribedil tic hypotension; and mental disorders (confusion, and to choose drugs with drug implicated (7). hallucinations, delusions, psychomotor agitation, patho- demonstrated efficacy instead. In 5 cases, the sleep attacks began logical gambling and hypersexuality) (ref 1). Rev Prescrire 2013; 33 (355): 351. within 3 days of taking the first dose. In piribedil one woman who had taken for Selected references from Prescrire’s literature 10 years with 2 interruptions, the sleep search. 1- iribedil is a dopamine agonist used attacks stopped after each discontinuation Prescrire Rédaction “12-4-4. Patients sous ago- P niste dopaminergique” Rev Prescrire 2012; 32 to treat Parkinson’s disease, but its and recurred each time the drug was (350 suppl. interactions médicamenteuses). efficacy is less well evaluated than that of reintroduced (7). 2- ANSM “RCP-Trivastal 50 mg LP + 20 mg com- primés” 21 December 2011: 10 pages. other dopamine agonists (1,2). It is also 3- Prescrire Rédaction “Les indications des médica- authorised in France as a “vasodilator” to Road traffic accidents, falls. Four ments dits “vasoactifs” en ophtalmologie. Le flou treat certain types of chronic cognitive and patients experienced sleep attacks while organisé” Rev Prescrire 2002; 22 (228): 330-331. 4- Prescrire Rédaction “Vasodilatateurs toujours neurosensory deficits in elderly patients, working or driving. One 56-year-old man remboursables” Rev Prescrire 2005; 25 (258): 99. intermittent claudication caused by chron- was admitted to hospital following sleep 5- ANSM “Commission d’AMM du 12 juillet 2012. Verbatim” 10 October 2012: 45 pages. ic peripheral artery occlusive disease, attacks that occurred two hours after his 6- Prescrire Rédaction “Accès soudains de sommeil and in ophthalmology, although its efficacy second dose of piribedil. One 75-year-old et antiparkinsoniens” Rev Prescrire 2004; 24 (256): in these indications has not been demon- man had an initial sleep attack while he 834-835. 7- Gouraud A et al. “Piribedil-induced sleep attacks strated (2-5). was driving, one hour after taking his in patients without Parkinson disease: a case series” Piribedil exposes patients to the first dose of piribedil. He felt the need to Clin Neuropharmacol 2011; 34 (3): 104-107. adverse effects of dopamine agonists, stop for a 10-minute nap. He had two 8- Prescrire Rédaction “Traitement de la maladie de Parkinson. Première partie: d’abord une monothé- including sudden sleep attacks, most of more attacks after resuming his journey, rapie par lévodopa ou agoniste dopaminergique” Rev which have been reported in patients the second of which caused a road traf- Prescrire 2011; 31 (329): 200-205. with Parkinson’s disease (a)(1,6). Does fic accident. One 86-year-old man taking this adverse effect also occur when piribedil for peripheral vascular disorders piribedil is used for other disorders, by had two falls caused by sleep attacks. The patients without Parkinson’s disease? A patients described these sleep attacks as case series published in 2011 provides intense and sudden. In all cases, the some answers to this question. sleep disorders resolved after discontin- uation of piribedil (7). Sudden sleep attacks, from the first few days of treatment. A group from the A direct role for piribedil. Sleep Lyon Regional Pharmacovigilance Cen- attacks are a known adverse effect of tre searched the French national phar- dopamine agonists. As most of the data macovigilance database for reports of came from patients with Parkinson’s dis- sleep attacks attributed to piribedil in ease, uncertainty remained over the role patients without Parkinson’s disease, of the disease in these sleep disorders (6). recorded between January 1988 and These case reports, in patients taking December 2008 (7). piribedil but who did not have Parkin- son’s disease, are consistent with this PRESCRIRE INTERNATIONAL NOVEMBER 2013/VOLUME 22 N° 143 • PAGE 265 Downloaded from english.prescrire.org on 27/09/2021 Copyright(c)Prescrire. For personal use only..
Load more

Recommended publications
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Ergot Alkaloids As Dopamine Agonists: Comparison in Two Rodent Models
    European Journal of Pharmacology, 37 (1976) 295-302 295 © North-Holland Publishing Company, Amsterdam - Printed in The Netherlands ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS GILL ANLEZARK, CHRIS PYCOCK and BRIAN MELDRUM Department of Neurology, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, U.K. Received 18 December 1975, revised MS received 20 February 1976, accepted 26 February 1976 G. ANLEZARK, C. PYCOCK and B. MELDRUM, Ergot alkaloids as dopamine agonists: comparison in two rodent models, European J. Pharmacol. 37 (1976) 295-302. A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protec- tive effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. The order of potency against audiogenic sei- zures was apomorphine> ergocornine> bromocryptine > ergometrine> LSD> methysergide > piribedil while that observed in the rotating mouse model was apomorphine> ergometrine> ergocornine> brornocryptine > piribedil. LSD caused only weak circling behaviour even when administered in high doses (> 1 mg/kg). Methyser- gide was ineffective. Prior administration of the neuroleptic agent haloperidol blocked the effect of DA agonists and of ergot alkaloids in both animal models. The possible action of ergot alkaloids as DA agonists is discussed. Ergot alkaloids Audiogenic seizures Dopamine agonists Circling behaviour 1. Introduction gic synapses, in two rodent pharmacological models. The first model studied is 'audiogen- The pharmacology of the ergot alkaloids is ic' seizures in genetically susceptible mice. complex and not well understood. Peripheral- The severity of the seizure responses to audi- ly, they act on smooth muscle as 5-hydroxy- tory stimulation can be modified by a variety tryptamine (5-HT) antagonists (Goodman and of drugs believed to act on monoaminergic Gilman, 1971) and as a-adrenergic blockers transmission in the brain (Lehmann, 1970).
    [Show full text]
  • Early Piribedil Monotherapy of Parkinson's Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repositório Científico do Centro Hospitalar do Porto Movement Disorders Vol. 21, No. 12, 2006, pp. 2110–2115 © 2006 Movement Disorder Society Early Piribedil Monotherapy of Parkinson’s Disease: A Planned Seven-Month Report of the REGAIN Study Olivier Rascol, MD, PhD,1* Bruno Dubois, MD,2 Alexandre Castro Caldas, MD,3 Stephen Senn, MD,4 Susanna Del Signore, MD,5 and Andrew Lees, MD,6 on behalf of the Parkinson REGAIN Study Group 1INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculte´deMe´decine, Toulouse, France 2INSERM U610/Groupe Hospitalier Pitie´-Salpeˆtrie`re, Paris, France 3Instituto de Cie¨nsas da Sau`de, Lisbon, Portugal 4Department of Statistics, University of Glasgow, Glasgow, United Kingdom 5Institut de Recherches Internationales Servier, Courbevoie, France 6Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London, United Kingdom Abstract: Piribedil is a D2 dopamine agonist, which has been significantly higher for piribedil (42%) than for placebo (14%) shown to improve symptoms of Parkinson’s disease (PD) when (OR ϭ 4.69; 95% CI ϭ 2.82–7.80; P Ͻ 0.001). Piribedil combined with L-dopa. The objective of this study was to significantly improved several UPDRS III subscores. UPDRS compare the efficacy of piribedil monotherapy to placebo in II improved on piribedil by Ϫ1.2 points, while it deteriorated patients with early PD over a 7-month period. Four hundred by 1.5 points on placebo (estimated effect ϭ 2.71; 95% CI ϭ and five early PD patients were randomized (double-blind) to 1.8–3.62; P Ͻ 0.0001).
    [Show full text]
  • Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain
    Neuropsychopharmacology (2009) 34, 651–661 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain ,1 1 1,2 O Chernoloz* , M El Mansari and P Blier 1 2 Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada Pramipexole (PPX) is a D2/D3 receptor agonist that has been shown to be effective in the treatment of depression. Serotonin (5-HT), norepinephrine (NE) and dopamine (DA) systems are known to be involved in the pathophysiology and treatment of depression. Due to reciprocal interactions between these neuronal systems, drugs selectively targeting one system-specific receptor can indirectly modify the firing activity of neurons that contribute to firing patterns in systems that operate via different neurotransmitters. It was thus hypothesized that PPX would alter the firing rate of DA, NE and 5-HT neurons. To test this hypothesis, electrophysiological experiments were carried out in anesthetized rats. Subcutaneously implanted osmotic minipumps delivered PPX at a dose of 1 mg/kg per day for 2 or 14 days. After a 2-day treatment with PPX the spontaneous neuronal firing of DA neurons was decreased by 40%, NE neuronal firing by 33% and the firing rate of 5-HT neurons remained unaltered. After 14 days of PPX treatment, the firing rate of DA had recovered as well as that of NE, whereas the firing rate of 5-HT neurons was increased by 38%.
    [Show full text]
  • Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’S Disease: a Network Meta- Analysis
    Cellular Physiology Cell Physiol Biochem 2018;45:119-130 DOI: 10.1159/00048625210.1159/000486252 © 2018 The Author(s).© 2018 Published The Author(s) by S. Karger AG, Basel Published online: online: January January 15, 15, 2018 2018 www.karger.com/cpbPublished by S. Karger AG, Basel 119 and Biochemistry www.karger.com/cpb Li et al.: Efficacy of Different Drugs on PD Accepted: October 09, 2017 This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Original Paper Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta- Analysis Bao-Dong Lia Jing-Jun Cuia Jia Songa Ce Qia Pei-Feng Maa Ya-Rong Wanga Jing Baib, aDepartment of Neurology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, bDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China Key Words Parkinson’s disease • Non-motor symptoms • UPDRS • Apomorphine • Efficacy • Drug therapy • Randomized controlled trials • Bayesian network model Abstract Background/Aims: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson’s disease (PD). Methods: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD.
    [Show full text]
  • Bromocriptine Treatment in Parkinson's Disease
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.39.2.184 on 1 February 1976. Downloaded from Journal ofNeurology, Neurosurgery, and Psychiatry, 1976, 39, 184-193 Bromocriptine treatment in Parkinson's disease J. D. PARKES, C. D. MARSDEN, I. DONALDSON, A. GALEA-DEBONO, J. WALTERS, G. KENNEDY, AND P. ASSELMAN From the University Department of Neurology, The Institute of Psychiatry, anzd King's College Hospital, London SYNOPSIS Thirty-one patients with Parkinson's disease were treated with the ergot alkaloid bromocriptine, a drug which stimulates dopamine receptors. Bromocriptine had a slight therapeutic effect in patients on no other treatmnent and an additional effect in patients on levodopa. The mean optimum dosage of bromocriptine, established over a 12 week period, was 26 mg daily. In 20 patients bromocriptine was compared with placebo in a double-blind controlled trial. Active treat- ment caused a significant (P <0.02) reduction in total disability and akinesia scores. The least disabled patients showed the greatest response. Side-effects of bromocriptine-nausea, vomiting, hallucinations, and abnormal involuntary movements-were similar in nature to those of levodopa.guest. Protected by copyright. In most normal subjects, bromocriptine causes an increase in plasma growth hormone concentration. This was determined in 20 patients with Parkinson's disease after 1-15 mg bromocriptine. Only a single patient showed an obvious increase up to 120 minutes after dosage. Bromocriptine was not effective treatment in two patients who had not previously responded to levodopa and replacement of this drug by bromocriptine in patients with end-of-dose akinesia after chronic levodopa treatment did not totally abolish response swings.
    [Show full text]
  • Side Effects of a Dopamine Agonist Therapy for Parkinson's Disease
    YALE JOURNAL OF BIOLOGY AND MEDICINE 89 (2016), pp. 37-47. ReView Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology Josip Anđelo Borovac* Department of Pathophysiology, University of Split School of Medicine, Croatia, EU Dopamine agonists (DA) are therapeutic agents that are commonly used in the treatment of Parkinson’s disease (PD). They can reduce undesired motor fluctuations and delay the administration of levodopa ther- apy. However, this drug family is associated with specific side effects that can significantly diminish the quality of life among PD patients. Some of them impose significant risks for individuals who have a his- tory of cardiovascular diseases, psychosis, and depression, or those older patients who suffer from renal or hepatic insufficiency. Various pharmacokinetic and pharmacodynamic considerations need to be taken into account when administering DA therapy. The goal of this review is to provide a comprehensive, up-to-date overview of DA therapeutic modalities for PD. INTRODUCTION are mediated by the prefrontal cortex (PFC) and domi- nantly implicated in reward and reinforcement pathways Dopamine agonists (DA) are chemical compounds (D3 to a lesser degree) [6,7]. it is reasonable to assume that that bind to dopamine receptors in the absence of the en- D2 receptors play an important role in psychotic behaviors dogenous neurotransmitter dopamine. Dopamine recep- since all efficacious antipsychotic drugs have the ability to tors are abundantly expressed in many tissues in the body, antagonize D2 receptors. The dopamine D3 receptor, lo- predominantly in the brain. Two families of dopamine re- cated in the limbic area of the brain, mediates drug-seek- ceptors have been identified.
    [Show full text]
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.
    [Show full text]
  • RCP Trivastal 50
    Trivastal Retard 50 SUMMARY OF PRODUCT CHARACTERISTICS TRIVASTAL Retard 50 INN : Piribedil NAME OF THE MEDICINAL PRODUCT TRIVASTAL Retard 50, sustained release coated tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Piribedil .............................................. 50 mg Excipients : q.s.f. one tablet PHARMACEUTICAL FORM Sustained release coated tablets. THERAPEUTIC INDICATIONS Adjunctive symptomatic treatment of chronic pathological cognitive and neurosensorial deficit in elderly subjects (excluding Alzheimer's disease and other dementia). Adjunctive treatment of intermittent claudication in chronic obliterating arteriopathies of the lower limbs (in stage 2). NB : this indication is based on studies in favour of improvement of the distance able to be walked. Proposed in ischaemic symptoms in ophthalmology. Treatment of Parkinson's disease : - either as monotherapy (treatment of forms with predominant tremor), - or in association with dopatherapy from the outset, or secondarily, particularly in forms with tremor. POSOLOGY AND METHOD OF ADMINISTRATION Oral route For all indications, except for treatment of Parkinson's disease : 1 tablet per day to be taken at the end of the main meal, or even 2 tablets per day in more severe cases in 2 administrations at the end of the 2 main meals. The tablets are to be swallowed with a half-glass of water, without chewing, at the end of meals. Treatment of Parkinson's disease : 04.2008 1/4 Trivastal Retard 50 - as monotherapy : 150 mg to 250 mg, i.e. 3 to 5 tablets per day, to be divided into 3 to 5 administrations per day. - as a supplement to dopatherapy: 80 to 140 mg (approximately 20 mg of piribedil per 100 mg of L.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector Clin Drug Investig (2014) 34:95–105 DOI 10.1007/s40261-013-0150-5 ORIGINAL RESEARCH ARTICLE Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects Willi Cawello • Seong R. Kim • Marina Braun • Jan-Peer Elshoff • Junji Ikeda • Tomoo Funaki Published online: 1 November 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com Abstract Results The pharmacokinetic analysis included 48 sub- Background and Objectives Rotigotine is a dopamine jects (24 Japanese, 24 Caucasian). The mean apparent dose receptor agonist with activity across the D1 through to D5 of rotigotine was 2.0 ± 0.5 mg for Japanese subjects and receptors as well as select serotonergic and adrenergic 2.08 ± 0.58 mg for Caucasians. Plasma concentration– sites; continuous transdermal delivery of rotigotine with time profiles of unconjugated rotigotine and of the main replacement of the patch once daily maintains stable metabolites were similar for both ethnic groups. Parameters plasma concentrations over 24 h. Rotigotine is indicated of model-independent pharmacokinetics, Cmax, time to for the treatment of early and advanced-stage Parkinson’s Cmax (tmax), and AUClast, for unconjugated rotigotine disease and moderate-to-severe idiopathic restless legs showed no statistically significant differences between syndrome. The pharmacokinetics and pharmacodynamics Japanese and Caucasian subjects. Values of concentration- of a drug may vary between subjects of different ethnic dependent pharmacokinetic parameters were higher in origin. This study evaluated the pharmacokinetics, safety, female subjects; this difference was minimized after cor- and tolerability of single-dose treatment with rotigotine rection for body weight.
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]